Clinical Trial Update: Low Dose Arsenic Trioxide as a Potential Chemotherapy Protector [Phase 2]

View source ↗

Summary

This Phase 2 clinical trial evaluated low-dose arsenic trioxide as a potential protector against chemotherapy toxicity in cancers other than leukemia. The study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Arsenic Trioxide (arsenic trioxide)

Snippet

Sponsor: The University of Texas Health Science Center at San Antonio | Conditions: Cancer Other Than Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2014-07-18